At a glance
- Originator Toyo Suisan Kaisha
- Developer Nonindustrial source; Toyo Suisan Kaisha
- Class Antineoplastics; Antiretrovirals; Glycolipids
- Mechanism of Action DNA-directed DNA polymerase inhibitors; RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; HIV infections
Most Recent Events
- 26 May 2001 No-Development-Reported for Cancer in Japan (Unknown route)
- 26 May 2001 No-Development-Reported for HIV infections treatment in Japan (Unknown route)
- 13 Nov 1998 New profile